Core Viewpoint - A class action lawsuit has been filed against Ardent Health, Inc. and its senior executives for securities fraud following a significant stock drop attributed to potential violations of federal securities laws [1][3]. Company Overview - Ardent Health, Inc. operates acute care hospitals and other healthcare facilities, with a focus on the collection of accounts receivable [4]. Allegations of Fraud - The lawsuit claims that Ardent Health misrepresented its process for determining the collectability of accounts receivable, stating it relied on "detailed reviews of historical collections," while in reality, it used a "180-day cliff" method to reserve accounts, leading to inflated receivable reports [4]. Stock Performance Impact - On November 12, 2025, Ardent Health disclosed a $43 million revenue decrease for the quarter and increased its professional liability reserves by $54 million, resulting in a stock price drop of $4.75 per share, or over 33%, from $14.05 to $9.30 [5]. Legal Proceedings - Investors have until March 9, 2026, to request to lead the case in the U.S. District Court for the Middle District of Tennessee, under the case caption Postiwala v. Ardent Health, Inc., et al. [3].

Core Viewpoint - A class action lawsuit has been filed against Oracle Corporation and certain senior executives for securities fraud, following significant stock drops attributed to potential violations of federal securities laws [1][3]. Company Overview - Oracle Corporation specializes in database software, enterprise applications, and cloud infrastructure and hardware, with a recent strategic shift towards cloud computing and AI infrastructure [4]. Allegations of Misleading Information - Oracle allegedly misled investors regarding its capital expenditures (CapEx) for AI infrastructure, claiming that increased spending would lead to rapid revenue and profit growth, while in reality, the rising CapEx did not yield meaningful near-term revenue [5]. Stock Performance and Impact - The stock price of Oracle dropped significantly after disclosures in September and December 2025, with a notable decline of $24.16 per share (nearly 11%) on December 11, 2025, following disappointing revenue growth and high CapEx reported on December 10, 2025 [6].

Core Viewpoint - SLM Corporation, also known as Sallie Mae, is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims of misleading statements regarding the company's loan delinquency rates and loss mitigation programs [1]. Summary by Relevant Sections Class Action Details - Investors in SLM securities from July 25, 2025, to August 14, 2025, can seek to be lead plaintiffs in the class action lawsuit titled Zappia v. SLM Corporation [1]. - The lawsuit alleges that SLM and its executives made false statements and failed to disclose significant increases in early-stage delinquencies [1]. Allegations Against SLM - The lawsuit claims that SLM overstated the effectiveness of its loss mitigation and loan modification programs, as well as the overall stability of its private education loan delinquency rates [1]. - A report from TD Cowen on August 14, 2025, indicated that July 2025 delinquencies increased by 49 basis points month-over-month, contradicting SLM's CFO's earlier assurances about normal seasonal trends [1]. Impact on Stock Price - Following the TD Cowen report, SLM's stock price fell by approximately 8%, reflecting investor concerns over the company's financial health [1]. Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows any investor who suffered losses during the class period to seek lead plaintiff status, which involves directing the class action lawsuit on behalf of all class members [1]. About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone [1]. - The firm has a strong track record, recovering $8.4 billion for investors over the past five years, including the largest securities class action recovery in history at $7.2 billion [1].

Core Viewpoint - The article discusses a securities fraud class action lawsuit against uniQure N.V. due to a significant delay in FDA approval for its drug candidate AMT-130, which led to a 49% decline in the company's stock price [1]. Summary by Relevant Sections Lawsuit Details - Investors who purchased shares of uniQure between September 24, 2025, and October 31, 2025, have until April 13, 2026, to file lead plaintiff applications in the class action lawsuit [1]. - The lawsuit alleges that uniQure and its executives failed to disclose material information, violating federal securities laws [1]. FDA Approval and Stock Impact - During the class period, uniQure indicated a high likelihood of receiving accelerated FDA approval for AMT-130 following a planned Biologics License Application (BLA) submission in Q1 2026 [1]. - On November 3, 2025, uniQure announced that the FDA no longer agreed that the data from Phase I/II studies were adequate for BLA submission, resulting in a stock price drop of $33.40, or over 49%, from $67.69 to $34.29 per share [1].

Core Viewpoint - Hagens Berman is notifying investors about a pending securities class action against F5, Inc. due to allegations of misleading statements regarding the security of its BIG-IP products, which resulted in significant financial losses for investors [1][2]. Summary by Relevant Sections Allegations and Investigation - The lawsuit claims that F5 executives misled the market about the security of its BIG-IP products, asserting that a sophisticated nation-state threat actor had long-term access to F5's systems and exfiltrated sensitive source code [2][9]. - The firm is investigating whether F5 delayed disclosing a material cybersecurity incident, which could have impacted investor decisions [3][9]. Financial Impact - Following the revelation of the security breach in October 2025, F5's market value dropped by over $2 billion, with significant stock price declines occurring after the disclosures [2][4]. - On October 27, 2025, F5 reported disappointing Q4 FY25 results, attributing the poor performance to the security breach, which led to reduced sales expectations and increased expenses for remediation efforts [9]. Class Action Details - The lead plaintiff deadline for the class action is set for February 17, 2026, covering the class period from October 28, 2024, to October 27, 2025 [4][5]. - Investors who purchased F5 shares during this period and experienced losses are encouraged to contact Hagens Berman for assistance [5][6].

Core Viewpoint - The lawsuit against BellRing Brands, Inc. alleges that the company and its executives misled investors regarding the true drivers of its sales growth, which was primarily due to retailers hoarding inventory rather than genuine consumer demand [2][4]. Group 1: Allegations and Impact - The lawsuit claims that BellRing's reported sales growth in 2025 was artificially inflated due to retailers stockpiling inventory to avoid previous supply chain shortages [2][9]. - Following the revelation of these practices, BellRing's share price experienced a significant drop, including a 33% decline in a single day after disappointing financial results were announced [2][9]. - The CFO of BellRing admitted that several key retailers had been hoarding inventory, which contradicted earlier assurances about the strength of consumer demand [9]. Group 2: Legal Proceedings and Investor Actions - Hagens Berman, a law firm specializing in securities fraud class actions, is leading the investigation and has set a lead plaintiff deadline of March 23, 2026, for investors who suffered losses [1][5]. - The firm is actively advising investors who purchased BellRing shares between November 19, 2024, and August 4, 2025, and are seeking to recover losses incurred during this period [5][6]. - The lawsuit highlights concerns about the sustainability of BellRing's competitive position, suggesting that the perceived strength was a result of temporary inventory practices rather than robust market demand [3][4].

Core Viewpoint - The F5 class action lawsuit alleges that F5, Inc. and its executives misled investors regarding the company's revenue outlook and growth potential, particularly in light of a significant security incident that impacted its operations and stock price [1][4]. Company Overview - F5, Inc. is a global multi-cloud application security and delivery company that enables customers to deploy, secure, and operate applications both on-premises and via public cloud [3]. Allegations of the Lawsuit - The lawsuit claims that F5 created a false impression of having reliable information about its revenue outlook while downplaying risks associated with seasonality and macroeconomic factors [4]. - It is alleged that F5's optimistic claims about its security capabilities were misleading, as the company was experiencing a significant security breach that jeopardized its clients' security and future prospects [4]. Impact of Security Incidents - On October 15, 2025, F5 disclosed a security breach involving a nation-state threat actor, which led to a nearly 14% drop in F5's stock price over two trading days [5]. - Following the breach, on October 27, 2025, F5 reported fourth-quarter fiscal year 2025 results that fell significantly below market expectations for fiscal 2026, attributing this to the security incident. This announcement caused an additional nearly 11% decline in stock price over two trading days [6]. Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased F5 securities during the Class Period to seek appointment as lead plaintiff in the class action lawsuit, representing the interests of all class members [7]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [8].

Core Viewpoint - A securities fraud class action lawsuit has been filed against Kyndryl Holdings, Inc. for alleged material misstatements and omissions regarding the company's cash management practices and internal controls over financial reporting [1]. Summary by Relevant Sections Lawsuit Details - The lawsuit is filed on behalf of investors who purchased Kyndryl securities between August 7, 2024, and February 9, 2026 [1]. - The case is registered in the United States District Court for the Eastern District of New York, under the title Brander v. Kyndryl Holdings, Inc., Case No. 1:26-cv-00782 (E.D.N.Y.) [1]. - Investors have until April 13, 2026, to file for lead plaintiff status [1]. Allegations - The complaint alleges that Kyndryl's financial statements during the class period were materially misstated [1]. - It is claimed that Kyndryl lacked adequate internal controls and materially understated issues related to these controls [1]. - The lawsuit states that Kyndryl would be unable to timely file its quarterly report on Form 10-Q with the SEC for the quarter ended December 31, 2025 [1]. - Defendants' statements regarding Kyndryl's business, operations, and prospects were allegedly materially false and misleading [1]. Investor Actions - Investors can retain counsel of their choice or take no action [1]. - They are encouraged to contact Kessler Topaz Meltzer & Check, LLP for a free case evaluation [1]. - The deadline to file for lead plaintiff status is April 13, 2026 [1].

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz continues its investigation of Baidu, Inc. ("Baidu†or the "Company†) (NASDAQ: BIDU) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON BAIDU, INC. (BIDU), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On November 26, 2025, Reuters reported that an October 7th letter from Deputy Defe. ...

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz continues its investigation of Alibaba Group Holding Ltd. ("Alibaba†or the "Company†) (NYSE: BABA) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON ALIBABA GROUP HOLDING LTD. (BABA), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On November 14, 2024, Financial Times published an a. ...